164 related articles for article (PubMed ID: 6364796)
1. Hyperglucagonemia in hepatic cirrhosis: its relation to hepatocellular dysfunction and normalization on recovery.
Kabadi UM; Eisenstein AB; Tucci J; Pellicone J
Am J Gastroenterol; 1984 Feb; 79(2):143-9. PubMed ID: 6364796
[TBL] [Abstract][Full Text] [Related]
2. Low serum T3 and raised reverse T3 levels in hepatic cirrhosis: role of glucagon.
Kabadi UM; Kabadi MU; Premachandra BN
Am J Gastroenterol; 1991 Oct; 86(10):1504-7. PubMed ID: 1928046
[TBL] [Abstract][Full Text] [Related]
3. Pancreatic glucoregulatory hormones in cirrhosis of the liver: portal vein concentrations during intravenous glucose tolerance test and in response to a meal.
Holst JJ; Burcharth F; Kühl C
Diabete Metab; 1980 Jun; 6(2):117-27. PubMed ID: 6997101
[TBL] [Abstract][Full Text] [Related]
4. Serum T3 and reverse T3 levels in hepatic cirrhosis: relation to hepatocellular damage and normalization on improvement in liver dysfunction.
Kabadi UM; Premachandra BN
Am J Gastroenterol; 1983 Nov; 78(11):750-5. PubMed ID: 6637968
[TBL] [Abstract][Full Text] [Related]
5. Hyperglucagonemia in cirrhosis: altered secretion and sensitivity to glucagon.
Sherwin RS; Fisher M; Bessoff J; Snyder N; Hendler R; Conn HO; Felig P
Gastroenterology; 1978 Jun; 74(6):1224-8. PubMed ID: 648812
[TBL] [Abstract][Full Text] [Related]
6. Studies of glucose intolerance in cirrhosis of the liver.
Shankar TP; Solomon SS; Duckworth WC; Himmelstein S; Gray S; Jerkins T; Bobal MA; Iyer RS
J Lab Clin Med; 1983 Oct; 102(4):459-69. PubMed ID: 6352838
[TBL] [Abstract][Full Text] [Related]
7. [Behavior of plasma insulin, C-peptide and glucagon in normal subjects and in patients with liver cirrhosis].
Gragnoli G; Tanganelli I; Signorini AM
Boll Soc Ital Biol Sper; 1980 Jan; 56(1):69-75. PubMed ID: 7002168
[TBL] [Abstract][Full Text] [Related]
8. Serum lipids, insulin, and glucagon after portacaval shunt in cirrhosis.
Shurberg JL; Resnick RH; Koff RS; Ros E; Baum RA; Pallotta JA
Gastroenterology; 1977 Feb; 72(2):301-4. PubMed ID: 830579
[TBL] [Abstract][Full Text] [Related]
9. Hyperglucagonemia in Laennec's cirrhosis. The role of portal-systemic shunting.
Sherwin R; Joshi P; Hendler R; Felig P; Conn HO
N Engl J Med; 1974 Jan; 290(5):239-42. PubMed ID: 4808927
[No Abstract] [Full Text] [Related]
10. Elevated circulating adiponectin levels in liver cirrhosis are associated with reduced liver function and altered hepatic hemodynamics.
Tietge UJ; Böker KH; Manns MP; Bahr MJ
Am J Physiol Endocrinol Metab; 2004 Jul; 287(1):E82-9. PubMed ID: 15010338
[TBL] [Abstract][Full Text] [Related]
11. [Blood glucose and glucoregulatory hormones in liver cirrhosis: a study of 24 hour profiles and of the role of portal-systemic shunting].
Marchesini G; Zoli M; Dondi C; Angiolini A; Forlani G; Melli A; Bianchi FB; Pisi E
Gastroenterol Clin Biol; 1982 Mar; 6(3):272-8. PubMed ID: 7047286
[No Abstract] [Full Text] [Related]
12. Elevated plasma ammonia level in hepatic cirrhosis: role of glucagon.
Kabadi UM; Eisenstein AB; Konda J
Gastroenterology; 1985 Mar; 88(3):750-6. PubMed ID: 3881308
[TBL] [Abstract][Full Text] [Related]
13. [Are disturbances of small intestinal motility associated with hyperglucagonemia in patients with liver cirrhosis?].
Chesta J; Generini G; Antezana C; Defilippi C
Rev Med Chil; 1992 Sep; 120(9):998-1002. PubMed ID: 1340993
[TBL] [Abstract][Full Text] [Related]
14. Early and late changes in fasting and absorptive plasma amino acids and ammonia after distal splenorenal shunt in cirrhosis.
Trevisani F; Bernardi M; Arienti V; Scrivano P; Mazziotti A; Cavallari A; Patrono D; Piazzi S; Gozzetti G; Gasbarrini G
Hepatology; 1994 Feb; 19(2):329-38. PubMed ID: 8294090
[TBL] [Abstract][Full Text] [Related]
15. Elevation of plasma glucagon-like immunoreactivity (GLI) in patients with liver cirrhosis.
Watanabe A; Hashimoto M; Higashi T; Kobayashi M; Nakatsukasa H; Yamauchi Y; Watanabe M; Fujiwara M; Nagashima H
J Med; 1986; 17(2):95-108. PubMed ID: 3473162
[TBL] [Abstract][Full Text] [Related]
16. [Plasma lipids, insulin, C-peptide, and glucagon levels in cirrhosis: personal observations].
Luca M; Sfogliano L; Privitera P; Noto R
Riv Eur Sci Med Farmacol; 1989 Apr; 11(2):113-22. PubMed ID: 2678305
[TBL] [Abstract][Full Text] [Related]
17. Glucose, insulin and somatostatin infusion for the determination of insulin resistance in liver cirrhosis.
Greco AV; Rebuzzi AG; Altomonte L; Manna R; Bertoli A; Ghirlanda G
Horm Metab Res; 1979 Oct; 11(10):547-9. PubMed ID: 521009
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of hyperinsulinemia and hyperglucagonemia after liver transplantation.
Sika M; Blair KT; Jabbour K; Williams PE; Donovan KL; Drougas JG; Becker YT; Bradley AL; Van Buren DH; Flakoll PJ; Chapman WC; Wright JK; Pinson CW
J Surg Res; 1997 Jul; 70(2):144-50. PubMed ID: 9245563
[TBL] [Abstract][Full Text] [Related]
19. Effects of transjugular intrahepatic portosystemic shunt (TIPS) on quantitative liver function tests.
Baron A; Gulberg V; Sauter G; Waggershauser T; Reiser M; Gerbes AL
Hepatogastroenterology; 1998; 45(24):2315-21. PubMed ID: 9951915
[TBL] [Abstract][Full Text] [Related]
20. Effects of glucose on hepatic conversion of aminonitrogen to urea in patients with cirrhosis: relationship to glucagon.
Hamberg O; Vilstrup H
Hepatology; 1994 Jan; 19(1):45-54. PubMed ID: 7903954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
